CHA2DS2-VASc versus CHADS2 for stroke risk assessment in low-risk patients with atrial fibrillation: A pilot study from a single center of the NCDR-PINNACLE registry

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 4, 2014, Pages 400-403

  Piyaskulkaew, Chatchawan ^a   Singh, Tejwant ^a   Szpunar, Susan ^b   Saravolatz II, Louis ^b   Rosman, Howard ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Atrial fibrillation; PINNACLE registry

Indexed keywords

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CONTROLLED STUDY; DISEASE REGISTRY; DRUG CONTRAINDICATION; DRUG INDICATION; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEASUREMENT PRECISION; OBSERVATIONAL STUDY; PILOT STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; AGED; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; COMPUTER PROGRAM; FACTUAL DATABASE; REGISTER; STROKE;

ANTICOAGULANT AGENT;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; HUMANS; PILOT PROJECTS; REGISTRIES; RISK ASSESSMENT; SOFTWARE; STROKE;

EID: 84899935138     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0983-z     Document Type: Article

References (13)

1. Stewart S, Hart CL, Hole DJ, McMurray JJ (2001) Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 86:516-521 (Pubitemid 32999861)
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370-2375 (Pubitemid 32424106)
3. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J (2010) Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121:e91
4. Lip GY (2011) Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost 9(Suppl 1):344-351
5. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864-2870 (Pubitemid 32537350)
6. Gallagher AM, Rietbrock S, Plumb J, van Staa TP (2008) Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 6(9):1500-1506
7. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263-272
8. Friberg L, Rosenqvist M, Lip GY (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33(12):1500-1510
9. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY (2012) The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 107(6):1172-1179. doi:10.1160/TH12-03-0175
10. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 57(11):e101-e198
11. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S (2006) Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation - executive summary. Circulation 114(7):e257-e354 (Pubitemid 44252297)
12. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH (2010) Guidelines for the management of atrial fibrillation. The task force of the management of atrial fibrillation of the European Society of Cardiology (ESC). Euro Heart J 31:2369-2429
13. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM, ROCKET AF Steering Committee and Investigators (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation 127(2):224-232